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LIVER DISEASE
Endothelin-1 contributes to maintenance of systemic
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Background and aims: Increased endothelin (ET)-1 activity may contribute to the complications of cirrhosis
and portal hypertension. The aim of this study was to assess the systemic and portal haemodynamic effects
of selective ET-A and ET-B receptor antagonism in patients with cirrhosis.
Methods: Sixteen patients with cirrhosis and portal hypertension (aged 52 (1) years, Pugh score 6.2 (0.3))
underwent 24 studies with infusions of: (A) selective ET-A antagonist, BQ-123 (n = 8), at 1000 and
3000 nmol/min; (B) selective ET-B antagonist, BQ-788 (n = 8), at 100 and 300 nmol/min; or (C) matched
saline placebo (n = 8) in a double blind randomised manner. Haemodynamic measurements were
performed through pulmonary artery, hepatic venous, and femoral artery catheters.
Results: Baseline patient characteristics were well matched. Compared with placebo, BQ-123 decreased
mean arterial pressure (MAP 215 (11) mm Hg (218%); p,0.02) and pulmonary vascular resistance
index (PVRI 281 (54) dyn6s6m2/cm5 (264%); p,0.05), with no effect on hepatic venous pressure
gradient (HVPG), cardiac index (CI), or systemic vascular resistance index (SVRI). Compared with
placebo, BQ-788 increased MAP (+11 (3) mm Hg (+12%); p,0.03) and SVRI (+1101 (709) dyn6s6m2/
cm5 (+50%); p,0.05), reduced CI (21.0 (0.4) l/min/m2 (229%); p = 0.05) with no effect on HVPG or
PVRI.
Conclusions: ET-1 contributes to maintenance of systemic and pulmonary haemodynamics without acutely
affecting HVPG in patients with early cirrhosis. In this group of patients, the use of selective ET-A and ET-B
antagonists for the management of variceal haemorrhage is likely to be limited.
E
ndothelin-1 (ET-1) was first identified by Yanagisawa
and colleagues in 19881 and is one of three 21 amino acid
peptides ET-1, ET-2, and ET-3. ET-1 has marked vascular
actions and is formed in the endothelium, liver, and other
tissues from the 38 amino acid precursor big ET-1 by
endothelin converting enzyme.2 ET-1 binds to two G coupled
receptors: endothelin-A (ET-A) and endothelin-B (ET-B)
receptors.3 Both receptors are found in vascular smooth
muscle where they mediate vasoconstriction, whereas in the
endothelium, ET-B receptors mediate vasodilatation in part
through nitric oxide release.3 Through these receptors, ET-1
provides a major contribution to maintenance of basal
vascular tone and blood pressure in humans.4
Plasma ET-1 concentrations are three times higher in
patients with cirrhosis than in healthy controls.5 The
concomitant rise in plasma big ET-1 concentrations suggests
that this is predominantly due to increased ET-1 synthesis.
The hepatic stellate cell (HSC) contributes to regulation of
intrahepatic resistance and is the primary hepatic origin of
increased ET-1 synthesis.5 Outside the liver, there are other
potential sources, including the kidney and vascular endothe-
lium, that may increase ET-1 release in response to
splanchnic arterial vasodilatation.6 In addition to increased
plasma ET-1 concentrations,7 8 patients with cirrhosis have
altered ET-A and ET-B receptor gene expression on HSC9
which correlates with the degree of portal hypertension in
human subjects.10 It is proposed that elevated concentrations
of ET-1 act on upregulated ET receptors on the HSC to cause
increased contractility and intrahepatic sinusoidal resistance,
resulting in portal hypertension. Furthermore, in the injured
liver, there appears to be a concurrent reduction in the
intrahepatic production of vasodilators, such as nitric oxide,11
leading to an imbalance in vascular mediators favouring
vasoconstriction that further exacerbates increased contrac-
tion of the HSC.
We hypothesised that inhibition of the endothelin system
in patients with liver cirrhosis and portal hypertension would
reduce portal pressure. Animal studies have supported this
hypothesis and demonstrated a fall in portal pressure with
both ET-A and ET-B receptor antagonism.12–15 Clinical studies
on forearm circulation have shown altered activity of the
endothelin system in cirrhosis, and that ET-1 contributes to
maintenance of basal vascular tone in patients with
cirrhosis.16 17 To date, there have been no controlled clinical
studies to investigate the acute haemodynamic effects of
systemic endothelin receptor antagonism in patients with
cirrhosis.
The aim of this randomised, double blind, placebo
controlled study was to investigate the acute systemic,
pulmonary, and portal haemodynamic effects of selective
ET-A and ET-B receptor antagonism in patients with cirrhosis
and portal hypertension.
Abbreviations: ET-1, endothelin-1; ET-A, endothelin A; ET-B,
endothelin B; MAP, mean arterial pressure; PVRI, pulmonary vascular
resistance index; HR, heart rate; SVRI, systemic vascular resistance
index; HSC, hepatic stellate cell; HVPG, hepatic venous pressure
gradient; FHVP, free hepatic venous pressure; WHVP, wedged hepatic
venous pressure; PAP, pulmonary artery pressure; PAWP, pulmonary
artery wedged pressure; MPAP, mean pulmonary artery pressure; RAP,
right atrial pressure; CO, cardiac output; CI, cardiac index; HBF, hepatic
blood flow; ICG, indocyanine green; PPHT, portopulmonary
hypertension
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PATIENTS AND METHODS
Patients
Patients with cirrhosis and portal hypertension were
recruited to the study with the approval of the local research
ethics committee, written informed consent from each
subject, and in accordance with the Declaration of Helsinki
of the World Medical Association. All patients with alcoholic
liver disease abstained from alcohol for at least one month
prior to and during the study period, confirmed by random
serum ethanol testing. All studies were performed following
an overnight fast. Exclusion criteria were age ,18 or
.75 years, regular vasoactive medication, hepatic venous
pressure gradient (HVPG) ,8 mm Hg, portal vein thrombo-
sis, a surgical portosystemic shunt or transjugular intra-
hepatic portosystemic stent shunt, significant comorbidity,
malignant disease, pregnancy, and women of childbearing
potential.
Haemodynamic measurements
All haemodynamic measurements and blood sampling were
performed in the supine position after an overnight fast and
starting at 08:00. After infiltration with 10 ml of 2% lidocaine,
a 9F introducer sheath (Avanti; Cordis Europa, Roden, the
Netherlands) was inserted into the right femoral vein using
the Seldinger technique. Under fluoroscopic guidance, a Swan
Ganz balloon tipped catheter (Edward Lifesciences
Corporation, Irvine, California, USA) was inserted into the
main right hepatic vein for measurement of the free (FHVP)
and wedged (WHVP) hepatic venous pressures, respectively.
All measurements were taken on a recorder capable of
producing permanent readings and designed for both venous
and arterial measurements (Hewlett Packard series 54 model
78339A). FHVP was measured with the catheter advanced into
the hepatic vein within 5 cm of the vena cava and after
stabilisation for up to 30 seconds. WHVP was obtained with
the balloon inflated and after stabilisation of tracings for up to
a minute. Measurements were repeated every 10 minutes with
the catheter in the same position, and by the same operator.
HVPG was defined as the difference between WHVP and
FHVP.
Using the same technique, a second 9F introducer sheath
(Avanti; Cordis Europa, Roden, the Netherlands) was
inserted into the right femoral vein. Through this, a
continuous cardiac output catheter (Edward Lifesciences
Corporation, Irvine, California, USA) was passed to the
pulmonary artery for measurement of free pulmonary artery
pressure (PAP), pulmonary artery wedged pressure (PAWP),
and mean PAP (MPAP). Right atrial pressure (RAP), cardiac
output (CO), and mixed venous oxygen saturation were
measured continuously using a Baxters Vigilance monitor
(Edward Lifesciences Corporation). Cardiac index (CI) was
calculated as CO/body surface area.
The femoral artery was cannulated using an arterial
catheter (Leader Cath; Vygon, Aachen, Germany) for
continuous measurement of arterial blood pressure
(Hewlett Packard series 54 model 78339A) and blood
sampling. Mean arterial pressure (MAP) was calculated as
diastolic blood pressure plus a third of pulse pressure.
Systemic vascular resistance index (SVRI) was calculated
as:
80 6 (MAP 2 RAP)/CI.
Pulmonary vascular resistance index (PVRI) was calculated
as:
80 6 (MPAP 2 PAWP)/CI.
Blood assays
Blood samples were obtained from the femoral vein in the
supine position after 30 minutes of rest. Blood (10 ml) was
admixed with 1 ml of 1% disodium EDTA and 1000 KIU
aprotinin (Bayer AG, Leverkusen, Germany). Samples were
immediately placed on ice and centrifuged at 1500 g for
20 minutes. Plasma was frozen and stored at 280 C˚ until
assayed. Following extraction using Bond Elut columns
(Varian, Harber City, California, USA), plasma concentra-
tions of ET-1 (Peninsula Laboratories Europe Ltd, St. Helens,
UK) and big ET-1 (Peninsula Laboratories Europe Ltd) were
determined by radioimmunoassay, as described previously.18
Intra-assay coefficients of variation for ET-1 and big ET-1
were 7.0% and 7.2%, respectively, and interassay coefficients
of variation were 9.0% and 9.3%, respectively.
Measurement of hepatic blood flow
Hepatic blood flow (HBF) was derived from measurement of
indocyanine green (ICG; Pulsion Medical Systems AG,
Munchen, Germany) clearance and extraction.19 ICG was
infused at the beginning of the study as a 10 mg intravenous
bolus followed by an infusion of 0.2 mg/min ICG. After an
equilibration period of 50 minutes, samples were taken
simultaneously from the right hepatic vein and peripheral
femoral vein in triplicate. Further samples were taken at 80
and 130 minutes. Peripheral and hepatic samples were
centrifuged at 1500 g for 20 minutes, and the optical density
of the supernatant determined. The value for optical density
was then plotted on a standard graph and the per cent
concentration extrapolated. The following formula was next
used to calculate HBF:
HBF = (ICG clearance/ICG extraction)/(12haematocrit)
= (Q/(Cp2Ch))/(12Haematocrit)
where Q is the infusion rate of ICG at 0.2 mg/min, and Cp
and Ch are peripheral and hepatic per cent concentrations
of ICG, respectively, derived as above. The final value for
HBF has to be multiplied by a factor of 100 to derive HBF in
ml/min. This method cannot be used if hepatic excretion
(Cp2Ch) is less than 10%.
Study protocol
This was a randomised, double blind, placebo controlled trial.
At the start of each study, 30 minutes was allowed for
equilibration of haemodynamic measurements. Patients were
then randomised to receive one of the following agents at
times 0 and 80 minutes: (1) pharmaceutical grade BQ-123
(Clinalfa AG, La¨ufelfingen, Switzerland) dissolved in saline
given at 1 ml/min at a dose of 1000 nmol/min, followed by a
further dose of 3000 nmol/min for 20 minutes at each
dose20 21 (protocol A, ET-A receptor antagonism); (2) phar-
maceutical grade BQ-788 (Clinalfa AG, La¨ufelfingen,
Switzerland) dissolved in saline given at 1 ml/min at a dose
of 100 nmol/min and 300 nmol/min for 20 minutes at each
dose20 21 (protocol B, ET-B receptor antagonism); or (3)
matched saline placebo administered twice (protocol C).
Patients were invited to attend for up to three independent
studies, with one study performed per day, and a separate
randomisation schedule was used for each patient to prevent
repetition of studies.
Statistical analysis
All results are expressed as mean (SD). All baseline
haemodynamic parameters were calculated after the 30 min-
ute period allowed for equilibrium. Parametric data were
analysed using the Student’s t test and Pearson’s correlation
as summary measures.22 The peak difference for each
haemodynamic variable was compared using the Student’s t
test. The Wilcoxon signed rank test and Spearman regression
analysis were used for non-parametric data. Statistical
analysis was performed using SPSS (version 9, Chicago,
Illinois, USA), and significance was taken at the 5% level.
Based on previous studies, we had a 90% power of detecting a
placebo adjusted clinically significant difference in: CI of
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0.37 l/min/m2, total peripheral vascular difference of
3.3 Wood units, MAP of 5.5 mm Hg, heart rate (HR) of
5.5 bpm, HBF of 32.5 ml/min, and HVPG of 3.1 mm Hg.
RESULTS
Of the 22 eligible patients, 18 patients were recruited into the
study. Four studies were terminated before completion due to
technical failure of instrumentation (n = 2), new onset of
atrial fibrillation (n = 1), or low HVPG of 4 mm Hg (n = 1).
One patient completed three studies, six completed two
studies each, and nine completed one study only, resulting in
24 studies in 16 patients. In patients who completed more
than one study, the mean time interval between studies was
61 (10) days. Baseline clinical characteristics of the patients
were well matched although WHVP was lower for patients
administered BQ-788 compared with placebo (tables 1, 2).
Systemic haemodynamic effects
Compared with placebo, BQ-123 reduced MAP (peak change
215 (11) mm Hg (218%); p,0.05) (fig 1) with a reflex
increase in HR (peak change +19 (7) bpm (+25%); p,0.05)
and reduction in RAP (peak change 24 (3) mm Hg (282%);
p = 0.003) but no effect on CI. There was a trend towards a
reduction in SVRI with BQ-123 (peak change 21194
(866) dyn6s6m2/cm5 (262%); p = 0.051). BQ-788 increased
MAP (peak change +11 (3) mm Hg (+12%); p,0.05) (fig 1)
and SVRI (peak change +1101 (709) dyn6s6m2/cm5 (+50%);
p,0.05), accompanied by a reduction in CI (peak change 21
(0.4) l/min/m2 (229%); p = 0.05) with no effect on HR or RAP.
Portal haemodynamic effects
HVPG did not change following administration of either drug
compared with placebo or when comparing the two drugs
(fig 2). It was not possible to derive HBF in seven studies due
to the hepatic excretion of ICG being less than 10%. The data
available did not reveal any changes in HBF following
administration of either BQ-788 (n = 7) or BQ-123 (n = 6)
compared with placebo (n = 4).
Pulmonary haemodynamic effects
Compared with placebo, BQ-123 appeared to reduce MPAP
(peak change 24 (3) mm Hg (229%); p = 0.08) and reduced
Table 1 Baseline clinical data
Variable Placebo (n = 8) BQ-123 (n = 8) BQ-788 (n = 8)
Age (y) (mean (SD)) 50 (4) 54 (7) 52 (9)
Sex (M/F) 8/0 7/1 8/0
Body mass index (kg/m2) 23 (3) 24 (2) 25 (3)
Child-Pugh score 6 (2) 6 (2) 6 (1)
Child-Pugh grade (A/B) 5/3 4/4 5/3
Ascites present 2 2 1
Varices 8 7 8
Bilirubin (mmol/l) 29 (16) 30 (17) 27 (24)
Albumin (g/l) 38 (6) 38 (8) 41 (7)
Prothrombin time (s) 12 (2) 11 (3) 11 (2)
Big ET-1 (pg/ml)* 79 (30) 68 (24) 60 (15) (n = 7)
ET-1 (pg/ml) 8 (3) 7 (2) 7 (1) (n = 7)
Aetiology
Alcoholic 6 5 6
Hepatitis C 2 3 2
Values are expressed as mean (SD).
ET, endothelin.
*Normal range 20260 pg/ml.
Normal range 0.525 pg/ml.
Table 2 Baseline haemodynamic variables
Variable Placebo (n = 8) BQ-123 (n = 8) BQ-788 (n = 8)
Systemic haemodynamics
HR (beats/min) 85 (20) 76 (9) 77 (17)
MAP (mmHg) 87 (17) 86 (11) 87 (10)
CI (l/min/m2) 4 (1) 5 (3) 4 (2)
SVRI (dyn6s6m2/cm5) 1960 (1046) 1935 (1141) 2148 (949)
Portal haemodynamics
WHVP (mm Hg) 24 (4) 22 (6) 18 (4)*
FHVP (mm Hg) 5 (4) 6 (2) 5 (4)
HVPG (mm Hg) 19 (5) 16 (6) 13 (4)
HBF (ml/min) 853 (397) (n = 4) 922 (925) (n = 6) 701 (283) (n = 7)
ICG hepatic concentration (mg/ml) 2 (1.5) 8 (17) 5 (10)
ICG peripheral concentration (mg/ml) 4 (1.4) 10 (16) 5 (3)
Pulmonary haemodynamics
PAWP (mm Hg) 4 (2) 5 (5) 5 (3)
RAP (mm Hg) 3 (2) 5 (3) 3 (4)
MPAP (mm Hg) 9 (2) 10 (5) 10 (4)
PVRI (dyn6s6m2/cm5) 134 (87) 135 (98) 150 (104)
Values are expressed as mean (SD).
HR, heart rate; MAP, mean arterial pressure; CI, cardiac index; SVRI, systemic vascular resistance index; WHVP,
wedged hepatic venous pressure; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient;
HBF, hepatic blood flow; ICG, indocyanine green; PAWP, pulmonary artery wedge pressure; RAP, right atrial
pressure; MPAP, mean pulmonary artery pressure; PVRI, pulmonary vascular resistance index.
*p,0.05 compared with placebo.
Normal range 4002600 ml/min.23
n = 8 unless otherwise stated.
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PVRI (peak change 281 (54) dyn6s6m2/cm5 (264%);
p,0.05) (fig 3). BQ-788 had no effect on MPAP or PVRI
compared with placebo.
Neurohormonal effects
Compared with placebo, BQ-788 caused an increase in
plasma ET-1 concentrations at the higher dose (peak change
+11 (2) ng/ml (+69%); p = 0.03). Compared with placebo,
there was no significant change in plasma concentrations of
ET-1 following BQ-123 administration, or big ET following
administration of either BQ-123 or BQ-788.
Drug tolerabili ty and adverse reactions
In addition to the patients above who were excluded after
randomisation, two patients who completed the studies had
adverse events. One patient randomised to BQ-788 developed
a vasovagal response to catheter withdrawal and responded
promptly to intravenous atropine and fluids. Following high
dose BQ-123 administration, a second pre-ascitic cirrhotic
patient with Child Pugh B disease developed symptomatic
hypotension, with MAP falling from 91 to 70 mm Hg. The
patient responded promptly to intravenous fluid administra-
tion. All patients were followed up in the clinic with no long
term side effects.
DISCUSSION
This is the first clinical study to investigate the acute
haemodynamic effects of selective ET-A and ET-B receptor
antagonism in patients with cirrhosis and portal hyperten-
sion. Using a rigorous randomised, double blind, placebo
controlled design, we have demonstrated that selective ET-A
and ET-B receptor antagonism reduced and increased
systemic blood pressure, respectively, but appeared to have
no effect on portal pressure.
In comparison with healthy volunteers where the mean
values of baseline plasma ET-1 are between 4 and 5 pg/ml,21
our study population had elevated plasma ET-1 concentra-
tions similar to levels found in patients with early cirrhosis,24
and is consistent with activation of the endothelin system as
a result of cirrhosis. Additional elevation of plasma ET-1, but
not big ET-1, concentrations with BQ-788 administration
supports the continuing role of the ET-B receptor in the
clearance of ET-1 in patients with cirrhosis.21 We have also
demonstrated that both ET-A and ET-B receptors have a role
in the maintenance of blood pressure in patients with
cirrhosis. The fall in blood pressure seen with BQ-123, and
the significant hypotension seen in one subject, suggests
increased sensitivity to ET-A receptor antagonism in patients
with cirrhosis and is consistent with our previous studies in
the peripheral circulation.24 This hypotension was accompa-
nied by a significant reduction in RAP that may reflect
reduced pulmonary vascular resistance. A reduction in SVRI
with BQ-123, as may be expected, just failed to reach
statistical significance (p = 0.051), possibly as a result of the
wide standard deviation. BQ-788 had the opposite effect on
the systemic circulation with an elevation in MAP and SVRI,
suggesting that BQ-788 acts mainly by vasoconstriction.
The absence of an effect of intravenous endothelin receptor
antagonism on HVPG in patients with cirrhosis and portal
hypertension is perhaps surprising. We speculate that this
may be explained by the potential contrasting consequences
of endothelin antagonism on the dynamic interplay between
the collateral, splanchnic, and intrahepatic circulations. One
might expect a reduction in intrahepatic resistance by ET
blockade and thereby reduce the ‘‘backward’’ component of
portal hypertension. In addition, ET-A receptor antagonism
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may result in vasodilatation of the collateral circulation and
hence reduce portocollateral resistance.25 However, ET-A
receptor antagonism may also cause splanchnic vasodilata-
tion and increase the ‘‘forward’’ component of portal
hypertension. Indeed, intravenous ET-1 infusion in healthy
volunteers caused abdominal pain and vasoconstriction of
the splanchnic circulation,26 suggesting a key role of ET-1 in
regulating splanchnic blood flow. Therefore, the theoretical
benefits of ET-A receptor blockade with reduced intrahepatic
resistance and portocollateral resistance have to be balanced
against the potential for splanchnic vasodilatation and
maintenance of portal hypertension. A complementary
argument could also be made for the absence of an effect
with ET-B receptor antagonism, although this is further
complicated by ET-B receptor mediated release of vasodila-
tors, such as nitric oxide and clearance of ET-1.21
The significant reduction in PVRI with ET-A receptor
blockade is an interesting observation of our study. This was
accompanied by a strong trend towards reduced MPAP
compared with placebo. There has been a lot of recent
interest in the use of endothelin receptor antagonists in
patients with pulmonary hypertension. Bosentan, a dual
endothelin receptor antagonist with 70-fold selectivity for the
ET-A receptor, improves symptoms and pulmonary haemo-
dynamics in patients with pulmonary hypertension.27–29 This
raises the question of whether endothelin antagonism may
be beneficial in patients with portopulmonary hypertension
(PPHT), although we did not include such patients in our
study. Plasma ET-1 concentrations are particularly elevated
in those patients with PPHT, implicating a role for ET-1 in the
pathogenesis of this condition.30 The effective reversal of
pulmonary hypertension would also have major implications
for those patients declined hepatic transplantation because of
the presence of severe PPHT. However, the use of endothelin
antagonists in patients with liver disease does present
problems. Both sitaxsentan, an ET-A receptor antagonist,
and bosentan have been associated with major disturbances
in hepatic function and, in one case with sitaxsentan, led to
fatal acute hepatitis.31 The adverse effects of bosentan appear
to be mediated through impairment in excretion of bile salts
and direct hepatotoxicity.32 Whether endothelin antagonism
will also produce beneficial haemodynamic effects and
improve symptoms in patients with PPHT without causing
detrimental effects on the liver requires further careful study.
Study limitations
A potential limitation of the study is that inadequate dosing
of antagonists may account for the absence of an effect on
portal haemodynamics. We have previously used similar
doses to achieve systemic haemodynamic effects in healthy
volunteers,20 21 and patients with renal33 and heart failure.34
Two different doses of BQ-123 and BQ-788 were used in the
same patient to assess the dose effect, and a lower dose was
administered first to ensure that it was tolerated prior to high
dose administration. Previous studies on healthy volunteers
have also shown that the maximum systemic haemodynamic
effects of BQ-123 and BQ-788 occurred at 50260 minutes,
hence a minimum observation period of 50 minutes follow-
ing administration of these agents.20 21 Although we observed
changes in systemic haemodynamic variables and plasma ET-
1 concentrations, we cannot completely exclude the possibi-
lity that the doses used may not have been sufficient to result
in effective receptor blockage in the portal circulation.
However, the use of higher doses of antagonists is likely to
reduce the clinical usefulness of these agents due to the
potential for detrimental effects on MAP.
Another limitation of the study is inclusion of three
patients with ascites. Ascitic patients are likely to have
more unstable haemodynamics, and are at greater risk of
detrimental systemic haemodynamic effects of vasoactive
agents.35 However, there were no qualitative differences in
the responses to the study drugs between those with and
without ascites. Despite inclusion of ascitic patients, most
were in Child Pugh class A, and results in patients with more
advanced cirrhosis may be different.
It would also be interesting to examine the effect of
combined ET-A and ET-B receptor blockade. Studies on
cirrhotic rats using the mixed antagonist bosentan have
demonstrated significant reductions in portal pressure and
hepatocollateral vascular resistance, with minimal systemic
effects.15 In the presence of ET-A receptor antagonism,
additional ET-B blockade may cause splanchnic vasodilation
resulting in better tolerance.36 The balance of these effects is
unknown but depending on tissue specific receptor expres-
sion, this combined approach may or may not provide
additional benefits.
In conclusion, this randomised double blind study demon-
strates that ET-1 contributes to systemic and pulmonary
haemodynamics in patients with early cirrhosis. The lack of
an acute effect on portal pressure despite systemic haemo-
dynamic effects suggests that selective endothelin receptor
antagonists are likely to have a limited role in the manage-
ment of variceal bleeding.
ACKNOWLEDGEMENTS
We wish to thank Sharon Cameron and the nursing staff at the
Wellcome Trust Clinical Research Facility for all their help with the
study. We also acknowledge the assistance of Ms Sue Lieper and Mr
Neil Johnston in sample analysis.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
D Tripathi, G Therapondos, J W Ferguson, P C Hayes, Department of
Hepatology, Royal Infirmary, Edinburgh, UK
D E Newby, Department of Cardiology, Royal Infirmary, Edinburgh, UK
D J Webb, Centre for Cardiovascular Science, The University of
Edinburgh, Western General Hospital, Edinburgh, UK
Conflict of interest: None declared.
REFERENCES
1 Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor
peptide produced by vascular endothelial cells. Nature 1988;332:411–15.
2 Masaki T, Yanagisawa M, Goto K. Physiology and pharmacology of
endothelins. Med Res Rev 1992;12:391–421.
3 La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp
Pharmacol Physiol 1995;22:315–23.
4 Haynes WG, Ferro CJ, O’Kane KP, et al. Systemic endothelin receptor
blockade decreases peripheral vascular resistance and blood pressure in
humans. Circulation 1996;93:1860–70.
5 Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in
liver disease and the hepatorenal syndrome. N Engl J Med
1992;327:1774–8.
6 Kapoor D, Redhead DN, Hayes PC, et al. Systemic and regional changes in
plasma endothelin following transient increase in portal pressure. Liver Transpl
2003;9:32–9.
7 Hartleb M, Kirstetter P, Moreau R, et al. Relationships between plasma
endothelin concentrations and the severity of cirrhosis. Gastroenterol Clin Biol
1994;18:407–12.
8 Mollier S, Gulberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in
cirrhosis—relations to systemic and splanchnic hemodynamics. J Hepatol
1995;23:135–44.
9 Yokomori H, Oda M, Yasogawa Y, et al. Enhanced expression of endothelin B
receptor at protein and gene levels in human cirrhotic liver. Am J Pathol
2001;159:1353–62.
10 Leivas A, Jimenez W, Bruix J, et al. Gene expression of endothelin-1 and ETA
and ETB receptors in human cirrhosis: Relationship with hepatic
hemodynamics. J Vasc Res 1998;35:186–93.
11 Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in
cirrhotic rat liver: endothelial dysfunction in portal hypertension.
Gastroenterology 1998;114:344–51.
12 De Gottardi A, Shaw S, Sagesser H, et al. Type A, but not type B, endothelin
receptor antagonists significantly decrease portal pressure in portal
hypertensive rats. J Hepatol 2000;33:733–7.
13 Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its
antagonist Bosentan on hemodynamics and microvascular exchange in
cirrhotic rat liver. J Hepatol 1998;28:1020–30.
1294 Tripathi, Therapondos, Ferguson, et al
www.gutjnl.com
14 Kojima H, Sakurai S, Kuriyama S, et al. Endothelin-1 plays a major role in
portal hypertension of biliary cirrhotic rats through endothelin receptor
subtype B together with subtype A in vivo. J Hepatol 2001;34:805–11.
15 Sogni P, Moreau R, Gomola A, et al. Beneficial hemodynamic effects of
bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive
rats. Hepatology 1998;28:655–9.
16 Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-
1 to basal vascular tone. Lancet 1994;344:852–4.
17 Helmy A, Newby DE, Jalan R, et al. Enhanced vasodilatation to endothelin
antagonism in patients with compensated cirrhosis and the role of nitric oxide.
Gut 2003;52:410–15.
18 Rolinski B, Sadri I, Bogner J, et al. Determination of endothelin-1
immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med (Berl)
1994;194:9–24.
19 Caesar J, Shaldon S, Chiandusi L, et al. The use of indocyanine green in the
measurement of hepatic blood flow and as a test of hepatic function. Clin Sci
1961;21:43–57.
20 Spratt JC, Goddard J, Patel N, et al. Systemic ETA receptor antagonism with
BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases
peripheral vascular resistance in healthy men. Br J Pharmacol
2001;134:648–54.
21 Strachan FE, Spratt JC, Wilkinson IB, et al. Systemic blockade of the
endothelin-B receptor increases peripheral vascular resistance in healthy men.
Hypertension 1999;33:581–5.
22 Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial
measurements in medical research. BMJ 1990;300:230–5.
23 Leevy CM, Mendenhall CL Lesko W, et al. Estimation of hepatic blood flow
with indocyanine green. J Clin Invest 1962;41:1169–79.
24 Helmy A, Jalan R, Newby DE, et al. Altered peripheral vascular responses to
exogenous and endogenous endothelin-1 in patients with well-compensated
cirrhosis. Hepatology 2001;33:826–31.
25 Chan CC, Wang SS, Lee FY, et al. Endothelin-l induces vasoconstriction on
portal-systemic collaterals of portal hypertensive rats. Hepatology
2001;33:816–20.
26 Bohm F, Pernow J, Lindstrom J, et al. ETA receptors mediate vasoconstriction,
whereas ETB receptors clear endothelin-1 in the splanchnic and renal
circulation of healthy men. Clin Sci 2003;104:143–51.
27 Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-
receptor antagonist bosentan in patients with pulmonary hypertension: a
randomised placebo-controlled study. Lancet 2001;358:1119–23.
28 Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin
receptor antagonist bosentan in patients with pulmonary arterial hypertension:
a 1-year follow-up study. Chest 2003;124:247–54.
29 Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial
hypertension. N Engl J Med 2002;346:896–903.
30 Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary
hypertension in decompensated cirrhosis with refractory ascites. Gut
2003;52:1355–62.
31 Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an
endothelin-A receptor antagonist, in patients with pulmonary arterial
hypertension: open-label pilot study. Chest 2002;121:1860–8.
32 Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan
inhibits the canalicular bile salt export pump: a potential mechanism for
hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223–31.
33 Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism
reduces blood pressure and increases renal blood flow in hypertensive
patients with chronic renal failure: a comparison of selective and combined
endothelin receptor blockade. Circulation 2004;109:1186–93.
34 Leslie SJ, Spratt JC, McKee SP, et al. Direct comparison of selective endothelin
A and non-selective endothelin A/B receptor blockade in chronic heart failure.
Heart 2005;91:914–19.
35 Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral
carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol
1996;25:909–15.
36 Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor
antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide
synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752–6.
EDITOR’S QUIZ: GI SNAPSHOT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Robin Spiller, Editor
Tracheal-oesophageal fistula in a patient with lung cancer
Clinical presentation
A 37 year old woman presented with a two month history of
a cough. A computed tomography (CT) scan performed in a
local hospital demonstrated a mass of the left hilum of the
lung and bronchioscopic biopsy confirmed the diagnosis of
lung cancer. The patient underwent infusion of antitumour
drugs into the bronchial artery and embolisation.
Three weeks postoperatively, the patient developed a cough
with sputum, fever, and evidence of aspiration. Five days
prior to transfer to our hospital, she deteriorated in spite of
antibiotics and full supportive treatment. On arrival, her CT
scan demonstrated consolidation in both lower lungs.
Subsequently, a non-ionic water soluble contrast swallow
examination confirmed a fistula (fig 1). It was evident that
the fistula was responsible for the patient’s serious symptoms
and lung infection.
Question
What was the likely cause of the fistula?
See page 1305 for answer
This case is submitted by:
Y S Guan
Y Liu
Department of Radiology, West China Hospital, Sichuan University,
Chengdu, Sichuan Province, China
Correspondence to: Dr Y S Guan, Department of Radiology, West China
Hospital, Sichuan University, 37# Guoxuexiang Street, Chengdu 610041,
Sichuan Province, China; YongsongGuan@yahoo.com
doi: 10.1136/gut.2005.084087
Figure 1 Non-ionic water soluble contrast swallow of the oesophagus
(left anterior oblique position). At the T5 level, the contrast agent
extravasated forward into the tracheal cavity (arrow).
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